Advertisement

Human Cell

, Volume 32, Issue 3, pp 231–239 | Cite as

Function of innate lymphoid cells in the immune-related disorders

  • Tanja Dzopalić
  • Biljana Božić-Nedeljković
  • Vladimir JurišićEmail author
Review Article
  • 115 Downloads

Abstract

Innate lymphoid cells (ILCs) are a recently described group of innate immune cells that mirror the characteristics of CD4+ T cell subsets. Based on their transcriptional factor and cytokine profile, ILCs family is divided into main subgroups—ILC1s, ILC2s, and ILC3s. Recently, one new subpopulation of ILCs with immunosuppressive characteristics has been described and named as regulatory ILCs. Various roles of ILCs have been confirmed including the role during the response to microbial signals, the role in inflammation and process of tissue repair. Function of ILCs is mediated through the cytokines production and direct cell-to-cell contact. This article summarizes in detail, the relationship between the ILCs and various immune-related disorders.

Keywords

Innate lymphoid cells Cytokines Inflammation Tissue repair 

Notes

Acknowledgements

The authors thank the support of the Ministry of Education, Science and Technological Development of the Republic of Serbia (projects numbers 175102, 175056).

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interest.

References

  1. 1.
    Origins TJ. On the origin of the immune system. Science. 2009;324:580–2.Google Scholar
  2. 2.
    Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol. 2012;30:647–75.Google Scholar
  3. 3.
    Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity. 2014;41:354–65.Google Scholar
  4. 4.
    Eberl G, Colonna M, Di Santo JP, et al. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348:6566.Google Scholar
  5. 5.
    Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol. 2011;12:21–7.Google Scholar
  6. 6.
    Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517:293–301.Google Scholar
  7. 7.
    Brestoff JR, Kim BS, Saenz SA, et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. 2015;519:242–6.Google Scholar
  8. 8.
    Lee MW, Odegaard JI, Mukundan L, et al. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell. 2015;160:74–87.Google Scholar
  9. 9.
    Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208:1127–33.Google Scholar
  10. 10.
    Wang S, Xia P, Chen Y, et al. Regulatory innate lymphoid cells control innate intestinal inflammation. Cell. 2017;171(201–216):e218.Google Scholar
  11. 11.
    Spits H, Artis D, Colonna M, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145–9.Google Scholar
  12. 12.
    Cortez VS, Colonna M. Diversity and function of group 1 innate lymphoid cells. Immunol Lett. 2016;179:19–24.Google Scholar
  13. 13.
    Fuchs A, Vermi W, Lee JS, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity. 2013;38:769–81.Google Scholar
  14. 14.
    Mjosberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016;138:1265–76.Google Scholar
  15. 15.
    Jurisić V, Stojacić-Djenić S, Colović N, Konjević G. The role of cytokine in regulation of the natural killer cell activity. Srp Arh Celok Lek. 2008;136(7–8):423–9.Google Scholar
  16. 16.
    Simoni Y, Newell EW. Dissecting human ILC heterogeneity: more than just three subsets. Immunology. 2018;153:297–303.Google Scholar
  17. 17.
    Roan F, Ziegler SF. Human group 1 innate lymphocytes are negative for surface CD3 epsilon but express CD5. Immunity. 2017;46:758–9.Google Scholar
  18. 18.
    Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011;12:1055–62.Google Scholar
  19. 19.
    Monticelli LA, Sonnenberg GF, Abt MC, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12:1045–54.Google Scholar
  20. 20.
    Salimi M, Barlow JL, Saunders SP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939–50.Google Scholar
  21. 21.
    Kim BS, Siracusa MC, Saenz SA, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5:170ra116.Google Scholar
  22. 22.
    Turner JE, Morrison PJ, Wilhelm C, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med. 2013;210:2951–65.Google Scholar
  23. 23.
    Roediger B, Weninger W. Group 2 innate lymphoid cells in the regulation of immune responses. Adv Immunol. 2015;125:111–54.Google Scholar
  24. 24.
    Liu M, Zhang C. The role of innate lymphoid cells in immune-mediated liver diseases. Front Immunol. 2017;8:695.Google Scholar
  25. 25.
    Hughes T, Becknell B, Freud AG, et al. Interleukin-1beta selectively expands and sustains interleukin-22 + immature human natural killer cells in secondary lymphoid tissue. Immunity. 2010;32:803–14.Google Scholar
  26. 26.
    Coccia M, Harrison OJ, Schiering C, et al. IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med. 2012;209:1595–609.Google Scholar
  27. 27.
    Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–42.Google Scholar
  28. 28.
    Hepworth MR, Monticelli LA, Fung TC, et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature. 2013;498:113–7.Google Scholar
  29. 29.
    Mortha A, Chudnovskiy A, Hashimoto D, et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science. 2014;343:1249288.Google Scholar
  30. 30.
    Melo-Gonzalez F, Hepworth MR. Functional and phenotypic heterogeneity of group 3 innate lymphoid cells. Immunology. 2017;150:265–75.Google Scholar
  31. 31.
    Cording S, Medvedovic J, Cherrier M, et al. Development and regulation of RORgammat(+) innate lymphoid cells. FEBS Lett. 2014;588:4176–81.Google Scholar
  32. 32.
    Yang Q, Bhandoola A. The development of adult innate lymphoid cells. Curr Opin Immunol. 2016;39:114–20.Google Scholar
  33. 33.
    Zook EC, Kee BL. Development of innate lymphoid cells. Nat Immunol. 2016;17:775–82.Google Scholar
  34. 34.
    Gasteiger G, Rudensky AY. Interactions between innate and adaptive lymphocytes. Nat Rev Immunol. 2014;14:631–9.Google Scholar
  35. 35.
    Pulendran B. The varieties of immunological experience: of pathogens, stress, and dendritic cells. Annu Rev Immunol. 2015;33:563–606.Google Scholar
  36. 36.
    Jiao L, Gao X, Joyee AG, et al. NK cells promote type 1 T cell immunity through modulating the function of dendritic cells during intracellular bacterial infection. J Immunol. 2011;187:401–11.Google Scholar
  37. 37.
    Halim TY, Steer CA, Matha L, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014;40:425–35.Google Scholar
  38. 38.
    Tumanov AV, Koroleva EP, Guo X, et al. Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe. 2011;10:44–53.Google Scholar
  39. 39.
    Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001;409:97–101.Google Scholar
  40. 40.
    Simoni Y, Fehlings M, Kloverpris HN, et al. Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency. Immunity. 2017;46:148–61.Google Scholar
  41. 41.
    Germain C, Meier A, Jensen T, et al. Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-gamma contributes to modulate immune responses. J Biol Chem. 2011;286:37964–75.Google Scholar
  42. 42.
    Dinarello CA, Novick D, Kim S, et al. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289.Google Scholar
  43. 43.
    Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells-how did we miss them? Nat Rev Immunol. 2013;13:75–87.Google Scholar
  44. 44.
    Abt MC, Lewis BB, Caballero S, et al. Innate immune defenses mediated by two ILC subsets are critical for protection against acute Clostridium difficile infection. Cell Host Microbe. 2015;18:27–37.Google Scholar
  45. 45.
    Klose CSN, Flach M, Mohle L, et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell. 2014;157:340–56.Google Scholar
  46. 46.
    Yang Z, Tang T, Wei X, et al. Type 1 innate lymphoid cells contribute to the pathogenesis of chronic hepatitis B. Innate Immun. 2015;21:665–73.Google Scholar
  47. 47.
    Braudeau C, Amouriaux K, Neel A, et al. Persistent deficiency of circulating mucosal-associated invariant T (MAIT) cells in ANCA-associated vasculitis. J Autoimmun. 2016;70:73–9.Google Scholar
  48. 48.
    Kim J, Kim G, Min H. Pathological and therapeutic roles of innate lymphoid cells in diverse diseases. Arch Pharm Res. 2017;40:1249–564.Google Scholar
  49. 49.
    Schepis D, Gunnarsson I, Eloranta ML, et al. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology. 2009;126:140–6.Google Scholar
  50. 50.
    Roan F, Stoklasek TA, Whalen E, et al. CD4+ group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis. J Immunol. 2016;196:2051–62.Google Scholar
  51. 51.
    Chen P, Vu T, Narayanan A, et al. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015;32:640–53.Google Scholar
  52. 52.
    Werth VP, Fiorentino D, Sullivan BA, et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 2017;69:1028–34.Google Scholar
  53. 53.
    Bromberg JF, Horvath CM, Wen Z, et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA. 1996;93:7673–8.Google Scholar
  54. 54.
    Martini M, Testi MG, Pasetto M, et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010;28:3548–57.Google Scholar
  55. 55.
    van Beek JJP, Martens AWJ, Bakdash G, et al. Innate lymphoid cells in tumor immunity. Biomedicines. 2016;4:7.Google Scholar
  56. 56.
    Dadi S, Chhangawala S, Whitlock BM, et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T Cells. Cell. 2016;164:365–77.Google Scholar
  57. 57.
    Halim TY. Group 2 innate lymphoid cells in disease. Int Immunol. 2016;28:13–22.Google Scholar
  58. 58.
    Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18:673–83.Google Scholar
  59. 59.
    Bousquet J, Clark TJ, Hurd S, et al. GINA guidelines on asthma and beyond. Allergy. 2007;62:102–12.Google Scholar
  60. 60.
    Kim HY, Umetsu DT, Dekruyff RH. Innate lymphoid cells in asthma: will they take your breath away? Eur J Immunol. 2016;46:795–806.Google Scholar
  61. 61.
    Drake LY, Kita H. Group 2 innate lymphoid cells in the lung. Adv Immunol. 2014;124:1–16.Google Scholar
  62. 62.
    Kabata H, Moro K, Koyasu S, et al. Group 2 innate lymphoid cells and asthma. Allergol Int. 2015;64:227–34.Google Scholar
  63. 63.
    Drake LY, Iijima K, Kita H. Group 2 innate lymphoid cells and CD4+ T cells cooperate to mediate type 2 immune response in mice. Allergy. 2014;69:1300–7.Google Scholar
  64. 64.
    Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363:1211–21.Google Scholar
  65. 65.
    Barlow JL, Bellosi A, Hardman CS, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol. 2012;129(191–198):e191–4.Google Scholar
  66. 66.
    Wilhelm C, Turner JE, Van Snick J, et al. The many lives of IL-9: a question of survival? Nat Immunol. 2012;13:637–41.Google Scholar
  67. 67.
    Lee S, Lane AP. Chronic rhinosinusitis as a multifactorial inflammatory disorder. Curr Infect Dis Rep. 2011;13:159–68.Google Scholar
  68. 68.
    Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma Immunology. J Allergy Clin Immunol. 2013;131:1479–90.Google Scholar
  69. 69.
    Ho J, Bailey M, Zaunders J, et al. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy. 2015;45:394–403.Google Scholar
  70. 70.
    Ebbo M, Crinier A, Vely F, et al. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017;17:665–78.Google Scholar
  71. 71.
    Kim BS, Wang K, Siracusa MC, et al. Basophils promote innate lymphoid cell responses in inflamed skin. J Immunol. 2014;193:3717–25.Google Scholar
  72. 72.
    Salimi M, Xue L, Jolin H, et al. Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production. J Immunol. 2016;196:45–54.Google Scholar
  73. 73.
    Moro K, Yamada T, Tanabe M, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463:540–4.Google Scholar
  74. 74.
    Williams CM, Rahman S, Hubeau C, et al. Cytokine pathways in allergic disease. Toxicol Pathol. 2012;40:205–15.Google Scholar
  75. 75.
    Pulendran B, Artis D. New paradigms in type 2 immunity. Science. 2012;337:431–5.Google Scholar
  76. 76.
    Zaiss DMW, Gause WC, Osborne LC, et al. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42:216–26.Google Scholar
  77. 77.
    Monticelli LA, Osborne LC, Noti M, et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA. 2015;112:10762–7.Google Scholar
  78. 78.
    Molofsky AB, Nussbaum JC, Liang HE, et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med. 2013;210:535–49.Google Scholar
  79. 79.
    Miller AM, Asquith DL, Hueber AJ, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107:650–8.Google Scholar
  80. 80.
    Spencer SP, Wilhelm C, Yang Q, et al. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science. 2014;343:432–7.Google Scholar
  81. 81.
    Kim HY, Lee HJ, Chang YJ, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014;20:54–61.Google Scholar
  82. 82.
    Neumann K, Karimi K, Meiners J, et al. A proinflammatory role of type 2 innate lymphoid cells in murine immune-mediated hepatitis. J Immunol. 2017;198:128–37.Google Scholar
  83. 83.
    Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med. 2015;21:698–708.Google Scholar
  84. 84.
    Malik TA. Inflammatory bowel disease: historical perspective, epidemiology, and risk factors. Surg Clin N Am. 2015;95:1105–22.Google Scholar
  85. 85.
    Pearson C, Thornton EE, McKenzie B, et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. Elife. 2016;5:e10066.Google Scholar
  86. 86.
    Longman RS, Diehl GE, Victorio DA, et al. CX(3)CR86(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med. 2014;211:1571–83.Google Scholar
  87. 87.
    Villanova F, Flutter B, Tosi I, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44 + ILC3 in psoriasis. J Investig Dermatol. 2014;134(4):984–91.Google Scholar
  88. 88.
    Teunissen MBM, Munneke JM, Bernink JH, et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients. J Investig Dermatol. 2014;134:2351–60.Google Scholar
  89. 89.
    Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683–747.Google Scholar
  90. 90.
    Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6:1167–75.Google Scholar
  91. 91.
    Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.Google Scholar
  92. 92.
    Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med. 2012;4:145ra106.Google Scholar
  93. 93.
    Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500–8.Google Scholar
  94. 94.
    Liu J, Duan Y, Cheng X, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407:348–54.Google Scholar
  95. 95.
    Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.Google Scholar
  96. 96.
    He S, Fei M, Wu Y, et al. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci. 2011;12:7424–37.Google Scholar
  97. 97.
    Pan B, Shen J, Cao J, et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 2015;5:16053.Google Scholar
  98. 98.
    Wu X, Yang T, Liu X, et al. IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer. Tumour Biol. 2016;37:5493–501.Google Scholar
  99. 99.
    Carrega P, Loiacono F, Di Carlo E, et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;6:8280.Google Scholar
  100. 100.
    Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Investig. 2008;118:534–44.Google Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Biomedical Research, Faculty of MedicineUniversity of NišNisSerbia
  2. 2.Faculty of BiologyUniversity of BelgradeBelgradeSerbia
  3. 3.Faculty of Medical SciencesUniversity of KragujevacKragujevacSerbia

Personalised recommendations